SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

ArticleAçık Erişim

Özet

Background: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population. © The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13302Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1093/bjs/znab101Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorNepogodiev, Dmitri
dc.contributor.authorBhangu, Aneel
dc.contributor.authorSimoes, Joana F.F.
dc.contributor.authorLi, Elizabeth
dc.contributor.authorPicciochi, Maria
dc.contributor.authorGlasbey, James C.
dc.contributor.authorAlser, Osaid
dc.contributor.authorBoccalatte, Luis A.
dc.contributor.authorDuran, Irani
dc.contributor.authorElhadi, Muhammed
dc.contributor.authorElmujtaba, Mohammed
dc.contributor.authorEmile, Sameh
dc.contributor.authorHarrison, Ewen M.
dc.contributor.authorHutchinson, Peter
dc.contributor.authorAllen Ingabire, J.C.
dc.contributor.authorIsik, Arda
dc.contributor.authorKamarajah, Sivesh K.
dc.contributor.authorKarandikar, Sharad
dc.contributor.authorKauppila, Joonas H.
dc.contributor.authorKembuan, Gabriele
dc.contributor.authorLederhuber, Hans
dc.contributor.authorLöffler, Markus W.
dc.contributor.authorMann, Harvinder
dc.contributor.authorMarson, Ella J.
dc.contributor.authorMclean, Kenneth A.
dc.contributor.authorMunyaneza, Emmanuel
dc.contributor.authorNorman, Lisa
dc.contributor.authorOmar, Omar M.
dc.contributor.authorPius, Riinu
dc.contributor.authorPockney, Peter
dc.contributor.authorRutegård, Martin
dc.contributor.authorStewart, Grant D.
dc.contributor.authorTaylor, Elliott H.
dc.contributor.authorVenn, Mary L.
dc.contributor.authorAhmed, Waheed-Ul-Rahman
dc.contributor.authorArgus, Leah
dc.contributor.authorBall, Alasdair
dc.contributor.authorBywater, Edward P.
dc.contributor.authorChaudhry, Daoud
dc.contributor.authorDawson, Brett E.
dc.contributor.authorGujjuri, Rohan R.
dc.contributor.authorJones, Conor S.
dc.contributor.authorKeatley, James M.
dc.contributor.authorLawday, Samuel
dc.contributor.authorOts, Riinu
dc.contributor.authorShaw, Catherine
dc.contributor.authorTrout, Isobel M.
dc.contributor.authorXu, William
dc.contributor.authorDajti, Irida
dc.contributor.authorGjata, Arben
dc.date.accessioned2026-10-18T20:28:08.498281881Z
dc.date.available2026-10-18T20:28:08.498281881Z
dc.date.issued2021
dc.description.abstractBackground: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population. © The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
dc.description.sponsorshipThis study was funded by a National Institute for Health Research (NIHR) Global Health Research Unit grant (NIHR 16.136.79) using UK aid from the UK government to support global health research, Association of Coloproctology of Great Britain and Ireland, Bowel & Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or UK Department of Health and Social Care.
dc.identifier.doi10.1093/bjs/znab101
dc.identifier.endpage1063
dc.identifier.issn0007-1323
dc.identifier.issue9
dc.identifier.pmid33761533
dc.identifier.scopus2-s2.0-85142233442
dc.identifier.startpage1056
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13302
dc.identifier.volume108
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofBJS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectComorbidity
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectElective Surgical Procedures
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPostoperative Complications
dc.subjectPreoperative Period
dc.subjectProspective Studies
dc.subjectSARS-CoV-2
dc.subjectVaccination
dc.subjectYoung Adult
dc.subjectclinical trial
dc.subjectelective surgery
dc.subjectepidemiology
dc.subjecthuman
dc.subjectimmunology
dc.subjectmulticenter study
dc.subjectpharmacology
dc.subjectpostoperative complication
dc.subjectprevention and control
dc.subjectprocedures
dc.subjectprospective study
dc.titleSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus119
rdl.oa.statusgold
rdl.source.indexSCOPUS